Baseline	follow‐up 7 weeks	follow‐up 15 weeks	follow‐up 27 weeks
		Benefits: PAIN during walking activities	PAIN during walking activities	PAIN during walking activities	PAIN during walking activities		Harms
dosage group		VAS pain median (range)	VAS pain median change (range)	VAS pain median change (range)	VAS pain median change (range)	General pain (% improvement at 27 weeks)	Adverse events
1ml	N = 7	43 (7 to 71)	7 (35 to 21)	1 (58 to 22)	6 (22 to 22)	0%	14% (1 patient reported mild to moderate pain)
2ml	N = 7	81 (46 to 100)	9 (−65 to 13)	7 (97 to 19)	7 (71 to 19)	0%	57% (4 patients reported mild to moderate pain)
3ml	N = 6	48 (24 to 87)	6 (39 to 10)	7 (41 to 2)	7 (87 to 17)	0%	17% (1 patient reported mild to moderate pain)
3x1ml	N = 6	61 (16 to 88)	29 (−78 to 7)	47 (78 to 26)	30 (78 to 26)	67%	17% (1 patient experienced severe pain)